Finally, having shown the most promise in neurodegenerative diseases, introducing these TCR molecules to a pre-stratified autologous CD4+ T cell population [32,38,39] could ensure both minimal cytotoxicity and a lack of rejection or induction of graft-versus-host disease (Figure 2). The gene discussed is CD4; the disease is neurodegenerative disease.